MPR10 小时
Wearable Furosemide Delivery System Approved for CKD Patients
The Food and Drug Administration (FDA) has expanded the approval of Furoscix® (furosemide injection) to include the treatment of edema in patients with ...
H.C. Wainwright维持scPharmaceuticals股票买入评级，目标价18美元
周五，H.C. Wainwright & ...
Pharmaceutical Technology on MSN5 天
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD
The US Food and Drug Administration (FDA) has approved scPharmaceuticals’ supplemental new drug application (sNDA) for ...
scPharmaceuticals announces FDA approval of Furoscix indication expansion
Pharmaceuticals (SCPH) announced that the FDA has approved the supplemental new drug application for Furoscix to expand the indication to ...
The Pharma Letter3 天
The week in pharma: action, reaction and insight – week to March 7
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...
Nasdaq5 天
ScPharma: FDA Approves FUROSCIX For Treating Edema In Chronic Kidney Disease Patients
(SCPH) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for FUROSCIX to expand the indication to include treatment of edema in ...
Renal & Urology News2 天
Wearable Furosemide Delivery System Approved for CKD Patients
Furoscix is expected to be available for CKD patients in April 2025. The Food and Drug Administration (FDA) has expanded the approval of Furoscix ® (furosemide injection) to include the treatment ...
The Pharma Letter5 天
FDA nod for scPharmaceuticals’ Furoscix sNDA
Cardiorenal specialist scPharmaceuticals has won US Food and Drug Administration (FDA) approval for its supplemental New Drug Application (sNDA) for Furoscix (furosemide injection) to expand the ...